Additionally, the FDA has approved Ipilimumab, Nivolumab, and Pembrolizumab for use as adjuvant therapy in high-risk melanoma, showing improved recurrence-free survival (RFS) and OS compared to high-dose IFN-α2b in resected high-risk melanoma [17]. Here, IFNA2 is linked to melanoma.